APPLICATIONS PUBLISHED 24 SEPTEMBER 2003
Published: 1-Mar-2004
The following patent applications are taken from the weekly European Patents Bulletin and give the publication number and date of publication as well as the title of the specification and the applicant. An asterisk denotes that application was made through the International Patent Cooperation Treaty (PCT). Further details on individual patent applications can be obtained from the EPO at Schottenfeldgasse 29, A-1072 Vienna. Tel: +43 1521 260 Fax: +43 1 52126 4492
The following patent applications are taken from the weekly European Patents Bulletin and give the publication number and date of publication as well as the title of the specification and the applicant. An asterisk denotes that application was made through the International Patent Cooperation Treaty (PCT). Further details on individual patent applications can be obtained from the EPO at Schottenfeldgasse 29, A-1072 Vienna. Tel: +43 1521 260 Fax: +43 1 52126 4492
Ionophore antibiotic formulations
Eli Lilly 1345587*
Sustained release drug delivery devices
Bausch & Lomb 1345588*
Solvent systems for pharmaceutical agents
Lyotropic Therapeutics 1345589*
Micellar colloidal pharmaceutical compsns containing a lipophilic active principle
CLL Pharma 1345590*
Pharmaceutical aerosol formulation
AstraZeneca 1345591*
Rapidly dispersing pharmaceutical compsns comprising effervescent agents
Pharmacia 1345592*
Lipid microparticles by cryogenic micronisation
Ares Trading 1345593*
Themoformable solid pharmaceutical compsn for controlled release of ivabradine
Les Laboratoires Servier 1345594*
Ion-strength independent sustained release pharmaceutical formulation
Solvay Pharmaceuticals 1345595*
Solvent for liquid ingredients to be used in effervescent products
Chemlink Laboratories 1345596*
Amphiphilic lipid nanoparticles for peptide and/or protein incorporation
Ares Trading 1345597*
The use of PPAR-Gamma agonists for treating diseases characterised by neuron degeneration, neuron injury or impaired plasticity
SmithKline Beecham 1345598*
Treatment of obsessive compulsive disorder
Orion Corp 1345599*
New clinical treatment
Nactilus 1345600*
Use of 5-hydroxy and 5-acyloxy-2,3-dihydro-4,6,7-trimethyl-2-benzo-furanacetic acid and their esters as agents useful for healing skin lesions and stimulants of angiogenesis
Biomedica Foscama Industria Chimico-Farmaceutica 1345601*
Treatment for neurogenetic disorders, impulse control disorders, and wound healing
University of Florida 1345602*
(Halo-benzo carbonyl)heterocyclo fused phenyl P38 kinase inhibition agents
Merck 1345603*
Antitumour therapy comprising distamycin derivatives
Pharmacia Italia 1345604*
Thermoformable solid pharmaceutical compsn for controlled release of perindopril
Les Laboratoires Servier 1345605*
Texaphyrin coordination compounds and uses thereof
Pharmacyclics 1345606*
Therapeutic combination of amlodipine and benazepril/benzeprilat
Novartis 1345607*
The use of selective dopamine D4 receptor agonists for treating sexual dysfunction
Abbott Laboratories 1345608*
Tetrahydro-(benzo or thieno)-azepine-pyrazine and triazine derivatives as MGLUR 1 antagonists
F Hoffmann-La Roche 1345609*
Method of treatment
AstraZeneca 1345610*
An antibiotic/analgesic formulation and a method of making their formulation
Phoenix Scientific 1345611*
Use of low molecular heparin for treating osteoarthritis
Aventis Pharma Deutschland 1345612*
Probiotic compounds derived from Lactobacillus casei strain KE01
Probiop Health 1345613*
Improved and stable extract from Hypericum perforatum L. method for the production thereof and its use as a topical medicament
Dr Willmar Schwabe 1345614*
Use of tinospoea extract in the treatment of immune system-modulated disorders
De Souza, Noel John; Yeole, Ravindra Dattatraya; Jha, Rasendrakumar; Bagchi, Sapna 1345615*
Reducing cellular damage in the human body
Morinda 1345616*
Methods of modulating toll-related receptor (TRR) signalling
Synovis 1345617*
Use of intermediate-conductance potassium channels and modulators for the diagnosis and treatment of illnesses having disturbed keratinocyte activity
Switch Biotech Aktiengesellschaft; Ludwig Maximilians Universitaet 1345618*
Use of a compsn for the stimulation of nerve growth, the inhibition of scar tissue formation, the reduction of secondary damage and/or the accumulation of macrophages
Migranen 1345619*
Stable enzymatic wound debrider
Healthpoint 1345620*
Salmonella vaccine
Akzo Nobel 1345621*
EIAV chimeric vaccine and diagnostic
Akzo Nobel 1345622*
Immunogenic proteoliposomes, and uses thereof
Dana-Farber Cancer Institute 1345623*
Induction of tolerance
Societe des Produits Nestle 1345624*
Methods for administering/dosing anti-RSV antibiotics for prophylaxis and treatment
Medimmune 1345625*
Novel pharmaceutical compsns based on anticholinergic agents and dopamine agonists
Boehringer Ingelheim Pharma 1345626*
Targeted modification of intracellular compounds
Centre National de la Recherche Scientifique; The Massachusetts General Hospital; Molecular Sciences Institute 1345627*
Conjugates of erythropoietin (PEP) with polyethylene glycol (PEG)
F Hoffmann-La Roche 1345628*
Particles for inhalation having sustained release properties
Advanced Inhalation Research 1345629*
Stabilised radiopharmaceutical compsns
Amersham 1345630*
